Internationally recognized services available through BC Cancer to internal and external researchers and collaborators include the following.
Genome Sciences Centre
The bioinformatics group has developed computational pipelines and databases to analyze and visualize genomic sequence information efficiently and at scale, and currently analyzes and processes more than 100 terabases of DNA sequence per month.
The core capabilities offered by the bioinformatics platform include:
The Genome Sciences Centre sequencing platform is a high-throughput large-scale DNA analysis facility that has been designed to maximize capacity while maintaining efficiency, scalability and flexibility. The platform is one of the largest platforms of its type in Canada and is well recognized internationally.The sequencing platform implements genomics, transcriptomics, proteomics, epigenomics, metagenomics and bioinformatics to support life sciences research with a focus on cancer.
Terry Fox Laboratory
BC Cancer Investigational Drug Program (IDP) provides fee-for-service preclinical research services and contract manufacturing for academic and private sector researchers. IDP’s mandate is to help its research partners develop promising therapeutic compounds to the point where they can be tested in early phase human clinical trials.
Deeley Research Centre
The Molecular and Cellular Immunology Core (MCIC) is a full service facility specializing in advanced molecular, genomic and histological methods including multicolour immunohistochemistry (mcIHC) and immunofluorescence (mcIF), automated image analysis, laser capture microdissection, multispectral flow cytometry, and single-cell sequencing.
MCIC supports academic and industry projects both nationally and internationally, ranging from investigator-driven basic research, to correlative studies for clinical trials, to fee-for-service projects with industrial clients.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.